Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment. Chemoresistance in glioblastoma is largely attributed to repair of temozolomide-induced DNA lesions by O6-methylguanine-DNA methyltransferase (MGMT). However, some MGMT-deficient glioblastomas are st...

Full description

Saved in:
Bibliographic Details
Published in:Brain (London, England : 1878) England : 1878), 2019-08, Vol.142 (8), p.2352-2366
Main Authors: Yi, Guo-Zhong, Huang, Guanglong, Guo, Manlan, Zhang, Xi'an, Wang, Hai, Deng, Shengze, Li, Yaomin, Xiang, Wei, Chen, Ziyang, Pan, Jun, Li, Zhiyong, Yu, Lei, Lei, Bingxi, Liu, Yawei, Qi, Songtao
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents, Alkylating
Brain Neoplasms - genetics
Brain Neoplasms - metabolism
Cytoplasmic Dyneins - genetics
Cytoplasmic Dyneins - metabolism
DNA Modification Methylases - deficiency
DNA Modification Methylases - genetics
DNA Repair - genetics
DNA Repair Enzymes - deficiency
DNA Repair Enzymes - genetics
Drug Resistance, Neoplasm - genetics
Glioblastoma - genetics
Glioblastoma - metabolism
Heterografts
Humans
Mice
Original
Temozolomide
Tumor Suppressor Proteins - deficiency
Tumor Suppressor Proteins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment. Chemoresistance in glioblastoma is largely attributed to repair of temozolomide-induced DNA lesions by O6-methylguanine-DNA methyltransferase (MGMT). However, some MGMT-deficient glioblastomas are still resistant to temozolomide, and the underlying molecular mechanisms remain unclear. We found that DYNC2H1 (DHC2) was expressed more in MGMT-deficient recurrent glioblastoma specimens and its expression strongly correlated to poor progression-free survival in MGMT promotor methylated glioblastoma patients. Furthermore, silencing DHC2, both in vitro and in vivo, enhanced temozolomide-induced DNA damage and significantly improved the efficiency of temozolomide treatment in MGMT-deficient glioblastoma. Using a combination of subcellular proteomics and in vitro analyses, we showed that DHC2 was involved in nuclear localization of the DNA repair proteins, namely XPC and CBX5, and knockdown of either XPC or CBX5 resulted in increased temozolomide-induced DNA damage. In summary, we identified the nuclear transportation of DNA repair proteins by DHC2 as a critical regulator of acquired temozolomide resistance in MGMT-deficient glioblastoma. Our study offers novel insights for improving therapeutic management of MGMT-deficient glioblastoma.
ISSN:0006-8950
1460-2156
DOI:10.1093/brain/awz202